On November 17, 2022 SynRx Therapeutics, a Hangzhou biopharma startup, reported that closed a $14 million Series Pre-A financing round to advance its portfolio of five oncology candidates (Press release, SynRx Therapeutics, NOV 17, 2022, View Source [SID1234624234]). The company focuses on solid tumor cancers with homologous recombination deficiency (HRD) – tumors that are unable to repair double-strand breaks (DSBs) in DNA, a condition that ultimately causes cancer . The company’s technology is based on original research from the lab of Founder and Chairman Xiaochun Yu. The round’s investors include Lapam Capital, Fenghua Venture, Westlake Innovation Capital and Long Yield Venture Capital.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!